Company
Lucira Health, Inc.
Headquarters: EmeryVille, CA, United States
Employees: 71
CEO: Mr. Erik T. Engelson
Market Cap
$18.4 Million
USD as of May 1, 2023
Lucira Health, Inc. Categories
United States Healthcare Diagnostics & ResearchUnited States Healthcare United States Diagnostics & Research
Top Competitors by Market Capitalization
Industry: Diagnostics & Research
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $207.62 B |
| Danaher | $171.89 B |
| Siemens Healthineers AG | $66.05 B |
| DexCom, Inc. | $46.50 B |
| IDEXX Laboratories, Inc. | $44.72 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Lucira Health, Inc. has the following listings and related stock indices.
Stock: NASDAQ: LHDX wb_incandescent